GUANFACINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H9Cl2N3O
Molecular Weight	246.093
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl

InChI

InChIKey=INJOMKTZOLKMBF-UHFFFAOYSA-N

InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)

HIDE SMILES / InChI

Molecular Formula	C9H9Cl2N3O
Molecular Weight	246.093
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019032s021lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdfhttps://www.medkoo.com/products/7825

Etiguanfacine, also known as SSP-1871, is an α2-adrenoreceptor agonist.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Alpha-2a adrenergic receptor 70 Target ID: CHEMBL1867 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019032s021lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/9605427	Agonist 2752		7.03 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019032s021lbl.pdf	Primary		Approved 8583	TENEX Approved Use Tenex (guanfacine hydrochloride) is indicated in the management of hypertension. Tenex may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Launch Date 1986
Attention deficit hyperactivity disorder 70 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	Primary		Approved 8583	TENEX Approved Use INTUNIV® is a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications Launch Date 1986

C_max

Value	Dose	Analyte	Population
2.5 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GUANFACINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
10 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GUANFACINE plasma	Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN
7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GUANFACINE plasma	Homo sapiens population: UNKNOWN age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
56 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GUANFACINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
162 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GUANFACINE plasma	Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN
116 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GUANFACINE plasma	Homo sapiens population: UNKNOWN age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
16 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:		GUANFACINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
30% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:		GUANFACINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
12 mg single, oral Overdose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23925253/	unhealthy, 12 years Health Status: unhealthy Age Group: 12 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/23925253/	Disc. AE: Hypertensive... AEs leading to discontinuation/dose reduction: Hypertensive (1%) Sources: https://pubmed.ncbi.nlm.nih.gov/23925253/
80 mg single, oral Overdose Dose: 80 mg Route: oral Route: single Dose: 80 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33069545/	unhealthy, 17 years Health Status: unhealthy Age Group: 17 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/33069545/	Disc. AE: Cardiogenic pulmonary edema... AEs leading to discontinuation/dose reduction: Cardiogenic pulmonary edema (1%) Sources: https://pubmed.ncbi.nlm.nih.gov/33069545/
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	unhealthy, children and adolescents Health Status: unhealthy Age Group: children and adolescents Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	Disc. AE: Somnolence, Fatigue... AEs leading to discontinuation/dose reduction: Somnolence (6%) Fatigue (2%) Hypotension (1%) Headache (1%) Dizziness (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf
4 mg 1 times / day steady, oral Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01069523	unhealthy, children Health Status: unhealthy Age Group: children Sources: https://clinicaltrials.gov/ct2/show/NCT01069523	Other AEs: Sedation, Fatigue... Other AEs: Sedation (below serious, 5 patients) Fatigue (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01069523

AEs

AE	Significance	Dose	Population
Hypertensive	1% Disc. AE	12 mg single, oral Overdose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23925253/	unhealthy, 12 years Health Status: unhealthy Age Group: 12 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/23925253/
Cardiogenic pulmonary edema	1% Disc. AE	80 mg single, oral Overdose Dose: 80 mg Route: oral Route: single Dose: 80 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33069545/	unhealthy, 17 years Health Status: unhealthy Age Group: 17 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/33069545/
Dizziness	1% Disc. AE	4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	unhealthy, children and adolescents Health Status: unhealthy Age Group: children and adolescents Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf
Headache	1% Disc. AE	4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	unhealthy, children and adolescents Health Status: unhealthy Age Group: children and adolescents Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf
Hypotension	1% Disc. AE	4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	unhealthy, children and adolescents Health Status: unhealthy Age Group: children and adolescents Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf
Fatigue	2% Disc. AE	4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	unhealthy, children and adolescents Health Status: unhealthy Age Group: children and adolescents Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf
Somnolence	6% Disc. AE	4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	unhealthy, children and adolescents Health Status: unhealthy Age Group: children and adolescents Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf
Fatigue	below serious, 3 patients	4 mg 1 times / day steady, oral Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01069523	unhealthy, children Health Status: unhealthy Age Group: children Sources: https://clinicaltrials.gov/ct2/show/NCT01069523
Sedation	below serious, 5 patients	4 mg 1 times / day steady, oral Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01069523	unhealthy, children Health Status: unhealthy Age Group: children Sources: https://clinicaltrials.gov/ct2/show/NCT01069523

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C8 1057 CYP2C19 2057 CYP3A4/5 296 CYP2B6 926	CYP3A4/5 91 P-gp 2052	CYP3A 142 CYP1A2 832 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s018lbl.pdf#page=16 Page: 16.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=15 Page: 15.0	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s018lbl.pdf#page=16 Page: 16.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s018lbl.pdf#page=16 Page: 16.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=15 Page: 15.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=15 Page: 15.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=15 Page: 15.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=15 Page: 15.0	no
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s018lbl.pdf#page=16 Page: 16.0	no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=15 Page: 15.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=10 Page: 10.0	major	yes (co-administration study) Comment: There was a significant decrease in the rate and extent of guanfacine exposure when co-administered with rifampin, a CYP3A4 inducer. The exposure to guanfacine decreased by 70% (AUC) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=10 Page: 10.0
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173033/ Page: 18.0	weak
CYP3A4/5 91	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=10 Page: 10.0	yes	yes (co-administration study) Comment: There was a substantial increase in the rate and extent of guanfacine exposure when administered with ketoconazole; the guanfacine exposure increased 3-fold (AUC) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022037lbl.pdf#page=10 Page: 10.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.tga.gov.au/sites/default/files/auspar-guanfacine-180503.pdf#page=30

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY546722	https://www.001chemical.com/chem/29110-47-2
AHH Chemical co.,ltd	MR-1013815	http://www.ahhchemical.com/product/MR-1013815.html
Alsachim	928	http://www.alsachim.com/product-C1246-glo.bal-view.html
Ambinter	Amb10843802	http://www.ambinter.com/reference/10843802
Angel Pharmatech	AG302778	http://www.angelpharmatech.com/29110-47-2.html
Angene	AGN-PC-04XZ20	http://www.angenechemical.com/productshow/AGN-PC-04XZ20.html
BioChemPartner	BCP09647	http://www.biochempartner.com/29110-47-2-BCP09647
BioCrick	BCC5180	http://www.biocrick.com/Guanfacine-BCC5180.html
BioSynth	J-017394	https://www.biosynth.com/en/products/all-products/products/J-017394.html
BLD Pharm	BD132435	http://www.bldpharm.com/products/29110-47-2.html
Chem Scene	CS-2787	http://www.chemscene.com/29110-47-2.html
Clearsynth	CS-T-25721	https://www.clearsynth.com/en/CST25721.html
CSNpharm	CSN11127	https://www.csnpharm.com/products/guanfacine.html
DC Chemicals	DC23226	http://www.dcchemicals.com/product_show-DC23226.html
Finetech	FT-0669067	http://www.finetechnology-ind.com/prod/detail/pub/29110-47-2.html
Finetech	FT-0669068	http://www.finetechnology-ind.com/prod/detail/pub/1189924-28-4.html
Hairui	HR141314	http://www.hairuichem.com/en/product/29110-47-2.html
Lab Network	LN01308386	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01308386
MedChem Express	HY-17416A	https://www.medchemexpress.com/guanfacine.html
Molcore	MC546722	https://www.molcore.com/product/29110-47-2
MuseChem	I003012	https://www.musechem.com/product/I003012.html
Smolecule	S576275	https://www.smolecule.com/products/s576275
Smolecule	S905071	https://www.smolecule.com/products/s905071
THE BioTek	bt-305246	https://www.thebiotek.com/product/others/bt-305246
Yuhao Chemical	RT3442	http://www.chemyuhao.com/29110-47-2.html

PubMed

Title	Date	PubMed
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.	2007-05-15	16950221
Differential noradrenergic influence on seizure expression in genetically Fast and Slow kindling rat strains during massed trial stimulation of the amygdala.	2007-02	17027042
Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast.	2006-12	17016709
Heme coordination states of unfolded ferrous cytochrome C.	2006-10-15	16877519
Discriminative stimulus properties of the selective and highly potent alpha2-adrenoceptor agonist, S18616, in rats: mediation by the alpha2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin.	2006-09	16814817
Relative contribution of intracellular and extracellular Ca2+ to alpha2-adrenoceptor-mediated contractions of ovine pulmonary artery.	2006-09	16787748
Yohimbine acts as a putative in vivo alpha2A/D-antagonist in the rat prefrontal cortex.	2006-07-24	16697527
Tourette's Syndrome.	2006-06	16650718
Syncope in children with Tourette's syndrome treated with guanfacine.	2006-03	16229000
New developments in the treatment of ADHD.	2006-01	16426101
Effect of noradrenergic system on the anxiolytic-like effect of DOI (5-HT2A/2C agonists) in the four-plate test.	2006-01	16307296
Noradrenergic modulation of space exploration in visual neglect.	2006-01	16261567
Mechanism of action of agents used in attention-deficit/hyperactivity disorder.	2006	16961428
Introduction: new developments in the treatment of attention-deficit/hyperactivity disorder.	2006	16961423
An open-label, prospective study of guanfacine in children with ADHD and tic disorders.	2005-11	16856436
Recent pharmacologic updates.	2005-10	16262586
Lack of effects of guanfacine on executive and memory functions in healthy male volunteers.	2005-10	16078088
Central sympathetic inhibition augments sleep-related ultradian rhythm of parasympathetic tone in patients with chronic heart failure.	2005-09	16127185
Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats.	2005-08	15714223
Animal models of attention-deficit hyperactivity disorder.	2005-07-15	16022733
Aripiprazole in children and adolescents: clinical experience.	2005-07	16159529
G-protein-coupled alpha2A-adrenoreceptor agonists differentially alter citrus leaf and fruit abscission by affecting expression of ACC synthase and ACC oxidase.	2005-07	15928018
Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors.	2005-07	15719216
Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions.	2005-06-01	15950011
The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.	2005-03	15794722
Impaired visuospatial divided attention in the spontaneously hypertensive rat.	2005-02-28	15639183
Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys.	2005-01-15	15652880
Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.	2005	16222911
Role of central sympathoexcitation in enhanced hypercapnic chemosensitivity in patients with heart failure.	2004-12	15632879
Guanfacine treatment of clozapine-induced sialorrhea.	2004-12	15538136
Noradrenergic alpha-2 agonists have anxiolytic-like actions on stress-related behavior and mesoprefrontal dopamine biochemistry.	2004-11-19	15494168
Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys.	2004-10-22	15451380
Alpha2 adrenergic agonists for the management of opioid withdrawal.	2004-10-18	15495025
Clonidine and guanfacine-induced antinociception in visceral pain: possible role of alpha 2/I2 binding sites.	2004-10-06	15464067
Methylphenidate an effective treatment for ADHD?	2004-10	15628613
Mania induction associated with atomoxetine.	2004-10	15349024
Pulse-synchronous sympathetic burst power as a new index of sympathoexcitation in patients with heart failure.	2004-10	15178546
New options in the pharmacological management of attention-deficit/hyperactivity disorder.	2004-07	15352538
Pharmacological management of attention-deficit hyperactivity disorder.	2004-06	15163276
Subtypes of alpha1- and alpha2-adrenoceptors mediating noradrenergic modulation of spontaneous inhibitory postsynaptic currents in the hypothalamic paraventricular nucleus.	2004-05	15117338
Potential noradrenergic targets for cognitive enhancement in schizophrenia.	2004-05	15115947
The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project: an open-label pragmatic randomised control trial comparing the efficacy of differing therapeutic agents for primary care detoxification from either street heroin or methadone [ISRCTN07752728].	2004-04-29	15117415
Loss of glutamatergic pyramidal neurons in frontal and temporal cortex resulting from attenuation of FGFR1 signaling is associated with spontaneous hyperactivity in mice.	2004-03-03	14999075
[Centrally-acting antihypertensive drugs].	2004-03	15171442
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.	2004-03	14733627
[Tourette syndrome: an analysis of its comorbidity and specific treatment].	2004-02	15011166
Pharmacotherapy of pervasive developmental disorders in children and adolescents.	2004	15584771
Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.	2004	15319020
The anticonvulsant and proconvulsant effects of alpha2-adrenoreceptor agonists are mediated by distinct populations of alpha2A-adrenoreceptors.	2004	15183527
Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?	2001	14728014

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Hypertension Initial dose: 1 mg orally once a day at bedtime; may increase to 2 mg once a day if satisfactory result not achieved after 3 to 4 weeks. Usual Pediatric Dose for Attention Deficit Disorder 6 YEARS TO LESS THAN 18 YEARS: Initial dose: 1 mg orally once a day, either in the morning or evening, at approximately the same time each day; may adjust in increments of no more than 1 mg/week. Recommended target dose: 0.05 to 0.12 mg/kg/day (total daily dose between 1 and 7 mg) once a day, depending on clinical response and tolerability Maximum dose: 6 to 12 years: Doses above 4 mg/day have not been evaluated; 13 to 17 years: Doses above 7 mg/day have not been evaluated.

Route of Administration: Oral

In Vitro Use Guide

Guanfacine and clonidine at relatively high concentrations (10(-6)-10(-4) M) produced contractions of the rat vas deferens which were antagonized by prazosin.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:50:14 GMT 2025` Edited by `admin` on `Mon Mar 31 17:50:14 GMT 2025`
Record UNII	30OMY4G3MK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GUANFACINE

Official Name

English

ESTULIC

Preferred Name

English

N-AMIDINO-2-(2,6-DICHLOROPHENYL)ACETAMIDE

Systematic Name

English

GUANFACINE [MI]

Common Name

English

GUANFACINE [VANDF]

Common Name

English

guanfacine [INN]

Common Name

English

NSC-759121

Code

English

BENZENEACETAMIDE, N-(AMINOIMINOMETHYL)-2,6-DICHLORO-

Systematic Name

English

Guanfacine [WHO-DD]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175554